Publications
Book
1. Hepatitis B Virus, 2nd Edition. Edited by CL Lai & S Locarnini.
International Medical Press (in press).
2. Hepatitis B Virus, 1st Edition. Edited by CL Lai & S Locarnini.
2002 International Medical Press.
Refereed Journals
1. Warner, N., Locarnini, S. 2008. The Antiviral Drug Selected
HBV rtA181T/sW172* Mutant Has A Dominant Negative Secretion Defect
And Alters The Typical Profile Of Viral Rebound. Hepatology (in
press).
2. Pawlotsky, J-M., Dusheiko, G., Hatzakis, A., Lau, D., Lau,
G.,Liang, T.J., Locarnini, S., Martin, P., Richman, D.D., Zoulim,
F. 2008. Virologic monitoring of hepatitis B virus therapy in
clinical trials and practice: recommendations for a standardized
approach. Gastroenterology;134:405-415.
3. Locarnini, S. Primary resistance, multidrug resistance and
cross-resistance pathways in HBV as a consequence of treatment
failure. Hepatology International (in press)
4. Chang JJ, Thompson AJ, Visvanathan K, Kent SJ, Cameron PU,
Wightman F, Desmond P, Locarnini SA, Lewin SR. 2007 The phenotype
of hepatitis B virus-specific T cells differ in the liver and
blood in chronic hepatitis B virus infection. Hepatology;46:1332-1340.
5. Sheldon, J., Ramos, B., Garcia-Samaniego, J., Rios, P., Bartholomeusz,
A., Romero, M., Locarnini, S., Zoulim, F., Soriano, V. 2007. Selection
of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected
and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With
Anti-HBV Activity. J Acquir Immune Defic Syndr;46:279-282.
6. Revill, P. A., Littlejohn, M., Ayres, A., Yuen, L., Colledge,
D., Bartholomeusz, A., Sasaduesz, J., Lewin, S. R., Dore, G. J.,
Matthews, G. V., Thio, C. L., Locarnini, S. A. 2007. Identification
of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis
B virus co-infected individuals. AIDS;21:1701-1710.
7. Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A.,
Ghany, M. G., Pawlotsky, J. M., Liaw, Y. F., Mizokami, M., Kuiken,
C. 2007. Antiviral drug-resistant HBV: standardization of nomenclature
and assays and recommendations for management. Hepatology;46:254-265.
8. Feld, J. J., Colledge, D., Sozzi, V., Edwards, R., Littlejohn,
M., Locarnini, S. A. 2007. The phenylpropenamide derivative AT-130
blocks HBV replication at the level of viral RNA packaging. Antiviral
Research;76:168-177.
9. Thompson, A. J., Ayres, A., Yuen, L., Bartholomeusz, A., Bowden,
D. S., Iser, D. M., Chen, R. Y., Demediuk, B., Shaw, G., Bell,
S. J., Watson, K. J., Locarnini, S. A., Desmond, P. V. 2007. Lamivudine
resistance in patients with chronic hepatitis B: role of clinical
and virological factors. J Gastroenterol Hepatol;22:1078-1085.
10. Warner, N., Locarnini, S., Kuiper, M., Bartholomeusz, A.,
Ayres, A., Yuen, L., Shaw, T. 2007. The rtL80I Substitution in
the Hepatitis B Virus Polymerase is Associated with Lamivudine
Resistance and Enhanced Viral Replication in Vitro. Antimicrob
Agents Chemother;51:2285-2292.
11. Heipertz, R. A., Jr., Miller, T. G., Kelley, C. M., Delaney,
W. E. th, Locarnini, S. A., Isom, H. C. 2007. In vitro study of
the effects of precore and lamivudine-resistant mutations on hepatitis
B virus replication. J Virol;81:3068-3076.
12. Yuen, L K W, A Ayres, M Littlejohn, D Colledge, A Edgely,
W J Maskill, S A Locarnini, and A Bartholomeusz. 2007. SEQHEPB:
A sequence analysis program and relational database system for
chronic hepatitis B. Antiviral Research;75:64-74.
13. Visvanathan K, Skinner NA, Thompson AJV, Riordan SM, Sozzi
T, Edwards R, Rodgers S , Kurtovic J , Chang J, Lewin S, Desmond
P ,Locarnini S. 2007. Regulation Of Toll-Like Receptor-2 Expression
In Chronic Hepatitis B By The Precore Protein. Hepatology;45:102-110.
14. Lau, G., Cooksley, H., Ribeiro, R., Power, K., Shudo, E.,
Bowden, S., Hui, CK., Mommeja-Marin, H., Sorbel, J., Mondou, E.,
Rousseau, F., Lewin, S., Perelson, A., Locarnini, S., Naoumov,
N. 2007. Impact Of Early Viral Kinetics On T-Cell Reactivity During
Antiviral Therapy In Chronic Hepatitis B. Antivir Ther;12:705-718.
15. Hui, C. K., Bowden, S., Zhang, H. Y., Wong, A., Lewin, S.,
Rousseau, F., Mommeja-Marin, H., Lee, N. P., Luk, J. M., Locarnini,
S., Leung, N., Naoumov, N. V., Lau, G. K. 2006. Comparison of
real-time PCR assays for monitoring serum hepatitis B virus DNA
levels during antiviral therapy. J Clin Microbiol;44:2983-7.
16. Riordan, S. M., Kurtovic, J., Skinner, N., Locarnini, S.,
McIver, CJ, Williams Visvanathan, K. 2006. Toll-like Receptor
Expression in Chronic Hepatitis C: Correlation with Pro-inflammatory
Cytokine Levels and Liver Injury. Inflamm. Res;55:279-285
17. Lim, S. G., Wai, C. T., Lee, Y. M., Dan, Y. Y., Sutedja,
D. S., Wee, A., Suresh, S., Wu, Y. J., Machin, D., Lim, C. C.,
Fock, K. M., Koay, E., Bowden, S., Locarnini, S., Ishaque, S.
M. 2006. A randomized, placebo-controlled trial of thymosin-alpha1
and lymphoblastoid interferon for HBeAg-positive chronic hepatitis
B. Antivir Ther;11:245-53.
18. Riordan, S. M., Skinner, N., Kurtovic, J., Locarnini, S.,
Visvanathan, K. 2006. Reduced expression of toll-like receptor
2 on peripheral monocytes in patients with chronic hepatitis B.
Clin Vaccine Immunol;13:972-974.
19. Matthews, G. V., Bartholomeusz, A., Locarnini, S., Ayres,
A., Sasaduesz, J., Seaberg, E., Cooper, D. A., Lewin, S., Dore,
G. J., Thio, C. L. 2006. Characteristics of drug resistant HBV
in an international collaborative study of HIV-HBV-infected individuals
on extended lamivudine therapy. AIDS;20:863-870.
20. Sung JJY, Chan JLY, Wong M-L, Bowden S, Liew C-T, Hui AY,
Wong VWS. Leung NWY, Locarnini S. 2005. Intrahepatic hepatitis
B virus covalently closed circular DNA can be a predictor of sustained
response to therapy. Gastroenterology;128:1890-1897.
21. Chan HLY, Tsui SKW, Tse CH, Ng EYT, Au TCC, Yuen L, Bartholomeusz
A, Leung KS, Lee KH, Locarnini S, Sung JJY. 2005. Epidemiology
and virological characteristics of two subgroups of genotype C
hepatitis B virus. J Infect Dis;191:2022-2032.
22. Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini
S, Kwong YL, Liang R, Lau GK. 2005. Sexual transmission of hepatitis
B infection despite the presence of hepatitis B virus immunity
in recipients of allogeneic bone marrow transplantation. J Clin
Virol;32:173-178.
23. Bell SJ, Lau A, Thompson A, Watson KJR, Demediuk B, Shaw
G, Chen RY, Ayres A, Yuen L, Bartholomeusz A, Locarnini SA, Desmond
PV. 2005. Chronic hepatitis B: Recommendations for therapy based
on the natural history of disease in Australian patients. J Clin
Virol;32:122-127.
24. Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K,
Lemon SM, Lau GKK, Beard MR. 2005. Cellular response to conditional
expression of the hepatitis B virus precore and core proteins
in cultured hepatoma (Huh-7) cells. J Clin Virol;32:113-121
25. Jazayeri MS, Basuni AA, Cooksley G, Locarnini S, Carman WF.
2004. Hepatitis B virus genotypes, core gene variability and ethnicity
in the Pacific region. J Hepatol;41:139-146.
26. Norder H, Courouce A-M, Coursaget P, Echevarria JM, Lee S-D,
Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. 2004. Genetic
diversity of hepatitis B virus strains derived worldwide: Genotypes,
subgenotypes and HBsAg subtypes. Intervirology;47:289-309.
27. Locarnini S, Hatzakis A, Heathcote J, Keeffe E, Liang TJ,
Mutimer D, Pawlotsky J-M, Zoulim F. 2004 Management of antiviral
resistance in patients with chronic hepatitis B. Antiviral Therapy;9:679-693.
28. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto
L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz
A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. 2004.
Clinical emergence of entecavir-resistant hepatitis B virus requires
additional substitutions in virus already resistant to lamivudine.
Antimicrob Agents Chemother;48:3498-3507.
29. Werle B, Bowden S, Locarnini S, Wursthorn K, Petersen J,
Lau G, Trepo C, Marcellin P, Goodman Z, Delaney IV WE, Xiong S,
Brosgart C, Chen S-S, Gibbs C, and Zoulim F. 2004. Persistence
of cccDNA during the natural history of chronic hepatitis B decline
during adefovir dipivoxil therapy. Gastroenterology;126:1750-1758,
30. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman
WF. 2004. Prevalence of HBsAg mutants and impact of hepatitis
B infant immunization in Four Pacific Island countries. Vaccine;22:2791-2799.
31. Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A,
Lau D, Locarnini S, Lewin SR. 2004. Comparison of sequence analysis
and a novel discriminatory real-time PCR assay for detection and
quantification of lamivudine-resistant hepatitis B virus strains.
J Clinical Microbiol;42:3809-3812.
32. Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ,
Roberts, SK. 2004. Hepatic failure due to fibrosing cholestatic
hepatitis in a patient with pre-surface mutant hepatitis B virus
and mixed connective tissue disease treated with prednisolone
and chloroquine. J Clinical Virol;31:53-57.
33. Jazayeri M, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini
S, Carman WF. 2004. HBV core sequence: definition of genotype-specific
variability and correlation with geographic origin. Vaccine;11:448-501.
34. Klein C, Bock CT, Wedemeyer H, Wustefeld T, Locarnini S,
Dienes HP. 2003. Inhibition of hepatitis B virus replication in
vivo by nucleoside analogues and siRNA. Gastroenterology;125:9-18.
35. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C,
Brosgart C, Colledge D, Edwards R, Bartholomeusz A, Locarnini
S. 2003. Resistance to Adefovir Dipivoxil therapy associated with
the selection of a mutation in the hepatitis B virus. Gastroenterology;125:292-297.
36. Schilling R, Ijaz S, Davidoff M, Lee J-Y, Locarnini S, Williams
R, Naoumov N. 2003. Endocytosis of hepatitis B immune globulin
into hepatocytes inhibits the secretion of hepatitis B virus.
J Virology;77:8882-8892.
37. Chen RYM, Bowden S, Desmond PV, Dean J, Locarnini SA. 2003.
Effects of interferon-? therapy on the catalytic domains of the
polymerase gene and basal core promoter, precore and core regions
of hepatitis B virus. J Gastro & Hepatol;18:630-637.
38. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch
A, Locarnini S, Sasadeusz J. 2003. Prevalence and Characterisation
of lamivudine-resistant hepatitis B virus mutations in HIV-HBV
co-infected individuals. AIDS;27:1649-1657.
39. Tallis, GF, Ryan, GM, Lambert, SB, Bowden, DS, McCaw, R.
Birch, CJ, Moloney, M, Carnie, JA, Locarnini, SA, Rouch, GJ, Catton,
MG. 2003. Evidence of patient-to-patient transmission of hepatitis
C virus through contaminated intravenous anaesthetic ampoules.
J Vir Hep;10:234-239.
40. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WEIV, Isom
H, Bowden S, Desmond P, Locarnini S. 2003. Effect of the G1896A
precore mutation on drug sensitivity and replication yield of
lamivudine-resistant HBV in vitro. Hepatology;37:27-35.
41. Ayres A, Bartholomeusz A, Lau G, Lam K-C, Lee, J-Y, Locarnini,
S. 2003. Lamivudine and Famciclovir resistant hepatitis B virus
associated with fatal hepatic failure. J Clinical Virol;27:111-116.
42. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer
H, Maertens G, Hulstaert F, De Vreese K, Sablon E. 2002. Monitoring
drug resistance in chronic hepatitis B virus (HBV)-infected patients
during lamivudine therapy: evaluation of performance of INNO-
LiPA HBV DR assay. J Clin Microbiol;40:3729-34
43. Lau GKK, He M-L, Fong DYT, Bartholomeusz A, Au W-Y, Lie AKW,
Locarnini S, Liang R. 2002. Pre-emptive use of lamivudine reduces
hepatitis B exacerbation reactivation after allogeneic hematopoietic
cell transplantation. Hepatology;36:702-709
44. Torresi J, Earnest-Silveira, L, Civitico G, Walters, TE,
Lewin SR, Fyfe, J, Locarnini SA. 2002. Restoration of replication
yield phenotype of lamivudine resistant hepatitis B virus mutants
by compensatory changes in the “fingers” sub-domain
of the viral polymerase selected as a consequence of vaccine escape
mutations in the “a” determinant of HBsAg. Virology;288:88-99.
45. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K Zhuang
H, Locarnini S, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity
of the hepatitis B virus HBsAg protein arising as a consequence
of sequence changes in the overlapping polymerase gene that are
selected by lamivudine therapy. Virology;293:305-13.
46. Delaney WE IV, Edwards R, Colledge D, Shaw T, Miller TG,
Isom HC, Furman P, Painter G, Locarnini S. 2002 Phenylpropenamide
derivatives AT-61 and AT-130 inhibit replication in both wild-type
and lamivudine-resistant strains of hepatitis B virus in vitro.
Antimicrob Agents Chemother;46:3057-3060
47. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden
D, Locarnini S. 2002. Hepatic iron overload does not prevent sustained
virological response to interferon-? therapy: A long term follow-up
study in hepatitis C-infected patients with ? thalassemia major.
Am J Gastro;97:982-987
48. Bonacini, M, Locarnini, S, Ayres, A, Kurz, A, Gibbs, C. 2002.
Fulminant hepatitis B due to a lamivudine-resistant mutant of
HBV in a patient coinfected with HIV. Gastroenterology;122:244-24
49. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini
S, Manns MP, Trautwein C. 2002. Selection of hepatitis B virus
polymerase mutants with enhanced replication by lamivudine treatment
after liver transplantation. Gastroenterology;122:264-273.
50. Colonno RJ, Genovese EV, Medina I, Lamb L, Durham SK, Huang
ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark
JM. 2001. Long-term entecavir treatment results in sustained antiviral
efficacy and prolonged life span in the woodchuck model of chronic
hepatitis infection. J Infect Disease;184:1236-1245.
51. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini
S, Perelson AS. 2001. Analysis of hepatitis B viral load decline
under potent therapy: Complex decay profiles observed. Hepatology;34:1012-1020.
52. Chin, R, Shaw, T, Sozzi, T, Trautwein, C, Bock, T, Manns,
M, Isom, H, Furman, P, Locarnini S. 2001. In vitro susceptibility
of wild type and drug resistant hepatitis B virus to (-)-?-D-2,
6 diaminopurine dioxolane (DAPD) and 2'-fluoro-5-methyl-?-L-arabinofuranosyluracil
(L-FMAU). Antimicrob Agents Chemother;45:2495-2501.
53. Delaney, WE, Edwards, R, Colledge, D, Shaw T, Torresi J,
Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini
S. 2001. Cross-resistance testing of antihepadnaviral compounds
using novel recombinant baculoviruses which encode drug-resistant
strains of hepatitis B virus. Antimicrob Agents Chemother;45:1705-1713.
54. Stuyver, L, Locarnini, SA, Lok, A, Hoofnagle, J, Richman,
DD, Schinazi, RF, and the Therapies for Viral Hepatitis International
Committee. 2001. Nomenclature for antiviral resistant human hepatitis
B virus mutants in the polymerase region. Hepatology;33:751-757.
55. Lee JY, Culvenor J, Angus P, Smallwood R, Nicoll A, Locarnini
SA. 2001. Duck hepatitis B virus replicative in primary bile duct
epithelial cells. J Virol;75:7651-7661.
56. Bock, CT, Schwinn, S, Locarnini, S, Fyfe, J, Manns, MP, Trautwein.
C, Zentgraf, H. 2001. Structural organization of the hepatitis
B virus minichromosome. J. Mol Biol;307:183-196.
57. Basuni, AA, Butterworth, LA, Cooksley, G, Locarnini S, Carman
WF. 2000. An efficient extraction method from blood clots for
studies requiring both host and viral DNA. J Viral Hepatitis;7:241-243.
58. Birch, CJ, McCaw, RF, Bulach, DM, Bowden, S, Carter, JT,
Tomnay, J, Hatch, B, Middleton, T, Chibo, D, Catton, M, Pankhurst,
JL, Breschkin, AM, Revill, P, Locarnini, S. 2000. Molecular analysis
of Human Immunodeficiency Virus strains associated with a case
of knowing and reckless transmission of HIV. J Infect Disease;182:941-944.
59. Wilson, N, Ruff, TA, Rana BJ, Leydon, J, Locarnini S. 2000.
The effectiveness of the infant hepatitis B immunisation program
in Fiji, Kiribati, Tonga and Vanuatu. Vaccine;18:3059-66.
60. Colledge, D, Civitico, G, Locarnini, S and Shaw, T. 2000.
In Vitro Antihepadnaviral activities of combinations of penciclovir,
lamivudine, and adefovir. Antimicrob Agents Chemother;44:551-560.
61. Nicoll A, Locarnini S, Chou ST, Smallwood R and Angus P.
2000. Effects of Corticosteroid and Nucleoside Analogue Therapy
On Duck Hepatitis B Viral Replication in Hepatocytes and Bile
Duct Epithelial Cells In Vivo. J Gastro & Hepatol;15:304-310
62. McCaughan, GW, Spencer, J, Koorey, D, Bowden, S, Bartholomeusz,
A, Verran, D, Chui, DD, Sheil, AGR, Jones RM, Locarnini, S, Angus,
P. 1999. Lamivudine therapy in patients undergoing liver transplantation
for hepatitis B virus precore mutant associated infection: High
resistance rates in treatment of recurrence but universal prevention
if used as a prophylaxis with very low dose HBIG. Liver Transplantation
& Surgery;5:512-519.
63. Kim, DK, Lee, N, Ryu, DH, Kim, YW, Kim, JS, Chang, K, Im,
GJ, Choi, WS, Cho, YB, Kim, KH, Colledge, D, Locarnini, S. 1999.
Synthesis and evaluation of 2-amino-9-)3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)
purines as potential prodrugs of penciclovir. Bioorg Med Chem;7:1715-25.
64. Loi, AG, Faraj, A, Pierra, C, Gosselin, G, Imbach, JL, Locarnini,
SA, Groman, EV, Schinazi, RF, Sommadossi, JP. 1999. Comparison
of anti-HBV activity of beta-D- and beta L-DDA-5' monophosphate
prodrugs and effectiveness in combination with lamivudine. Nucleosides
Nucleotides;18:1005-6.
65. Hardikar, W, Moaven, LD, Bowden, DS, Locarnini, SA, Smith
AL. 1999. Hepatitis G: viroprevalence and seroconversion in a
high-risk group of children. J Viral Hepatitis;6:337-341.
66. Torresi J, Li F, Locarnini SA and David Anderson. 1999. Only
the non-glycosylated fraction of hepatitis E virus capsid (open
reading frame 2) protein is stable in mammalian cells. J Gen Virol;80:1185-88.
67. Lau GKK, Carman W, Locarnini S, Okuda K, Williams R and Lam
SK. 1999. Report of consensus meeting on "Treatment of chronic
HBV infection: Asia-Pacific 1997". J Gastro Hepatol;14:3-12.
68. Nicoll AJ, Colledge, DL, Toole JJ, Angus PW, Smallwood, RA
and Locarnini SA. 1998. Inhibition of Duck Hepatitis B Virus Replication
by 9-(2-Phosphonylmethoxyethl) adenine (PMEA), an Acyclic Phosphonate
Nucleoside Analogue. Antimicrob Agents Chemother;42:3130-3135.
69. Bartholomeusz A. Groenen L and Locarnini SA. 1998. Clinical
experience with famciclovir against Hepatitis B virus and development
of resistance. Intervirology;40:337-342.
70. de Man RA, Bartholomeusz A, Niesters HGM, Zondervan PE, Locarnini
S. 1998. The sequential occurrence of viral mutations in a liver
transplant recipient re-infected with hepatitis B virus: Hepatitis
B Immune Globulin Escape, Famciclovir Non-Response, followed by
lamivudine resistance resulting in graft loss. J.Hepatology;29:669-675.
71. Lin E, Luscombe C, Colledge D, Wang YY and Locarnini S. 1998.
Long Term Therapy with the Guanosine Nucleoside Analogue Penciclovir
Controls Chronic Duck Hepatitis B Virus Infection In Vivo. Antimicrob
Agents Chemother;42:2132-2137.
72. Ostapowicz G, Watson KJR, Locarnini S and Desmond PV. 1998.
Role of alcohol in the progression of liver disease due to hepatitis
C virus infection. Hepatology;27:1730-1735.
73. Druce JD, Robinson WF, Locarnini SA, Kyaw-Tanner MT, Sommerlad
SF and Birch CJ. 1997. Transmission of human and feline immunodeficiency
viruses via reused suture material. J Med.Virol;53:13-18.
74. Torresi J, Meanger J, Lambert P, Li F, Locarnini SA and Anderson
DA. 1997. High level expression of the capsid protein of hepatitis
E virus in diverse eukaryotic cells using the Semliki Forest virus
replicon. J Virol Meth;69:81-91.
75. Colledge D, Locarnini S, Shaw T. 1997. Synergistic inhibition
of hepadnaviral replication by lamivudine in combination with
penciclovir in vitro. Hepatology;26:216-225.
76. Moaven LD, Bowden DS, Young IF, Locarnini SA. 1997. Prevalence
of hepatitis G virus antibodies in Queensland blood donors. Med
J Aust;166,507-509.
77. McCaw R, Moaven LD, Locarnini SA, Bowden DS. 1997. Hepatitis
C virus genotypes in Australia. J Viral Hepatitis;4:351-357.
78. Moaven LD, Locarnini SA, Bowden DS, Kim J, Brechkin A, McCaw
R, Yun A, Wages J, Jones B, Angus P. 1997. Hepatitis G virus and
fulminant hepatic failure: evidence for transfusion related infection.
J Hepatol;27:613-619.
79. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan
J, Angus P and Locarnini S. 1997. Hepatitis B virus polymerase
mutations during antiviral therapy in a patient following liver
transplantation. J Hepatol;26:1148-1153.
80. Bartholomeusz, AI, Guo K-J, Edwards PC, Locarnini SA. 1996.
Hepatitis C virus (HCV) RNA polymerase assay using cloned HCV
non-structural proteins. Antiviral Therapy;1:18-24.
81. Moaven LD, Hyland CA, Young IF, Bowden DS, McCaw R, Mison
L and Locarnini S. 1996. Prevalence of hepatitis G virus in Queensland
blood donors. Med J Aust;165:369-371.
82. Moaven LD, Tennakoon PS, Bowden DS and Locarnini SA. 1996.
Mother-to-baby transmission of hepatitis G virus. Med J Aust;165:84-85.
83. McCaughan G, Angus P, Bowden S, Shaw T, Breschkin A, Locarnini
S. 1996. Retransplantation for precore mutant-related chronic
hepatitis B infection: Prolonged survival in a patient receiving
sequential ganciclovir/famciclovir therapy. Liver Transplantation
and Surgery;2:472-474.
84. Locarnini SA, Civitico G and Newbold J. 1996 Hepatitis B:
New approaches for antiviral chemistry. Antiviral Chemistry &
Chemotherapy;7:53-64.
85. Locarnini S and Luscombe C. 1996. Pathogenic effects of antiviral
therapy in chronic hepatitis B. Antiviral Therapy;1(Suppl):59-63.
86. Nicoll AJ, Angus PW, Chou ST, Luscombe CA, Smallwood RA and
Locarnini SA. 1997. Demonstration of duck hepatitis B virus in
bile duct epitheliel cells: Implications for pathogenesis and
persistent infection. Hepatology;25:463-469
87. Shaw T, Mok SS and Locarnini SA. 1996. Inhibition of hepatitis
B virus DNA polymerase by enantiomers of penciclovir triphosphate
and metabolic basis for selective inhibition of HBV replication
by penciclovir. Hepatology;24:996-1002.
88. McMillan JS, Bowden DS, Angus PW, McCaughan GW and Locarnini
SA. 1996. Mutations in the hepatitis B virus precore/core gene
and core promoter in patients with severe recurrent disease following
liver transplantation. Hepatology;24:1371-1378.
89. Luscombe CA, Pedersen J, Uren E and Locarnini S. 1996. Long-term
ganciclovir chemotherapy of congenital duck hepatitis B virus
infection in vivo: effect on intrahepatic viral DNA, RNA and protein
expression. Hepatology;24:766-773.
90. Fuller A, Moaven L, Spelman D, Spicer WJ, Wraight H, Curtis
D, Leydon J, Doultree J and Locarnini S. 1996. Parvovirus B19
in HIV infection: A treatable cause of anemia. Pathology;28:277-280.
91. Civitico G, Shaw T and Locarnini S. 1996. Interaction between
ganciclovir and foscarnet as inhibitors of duck hepatitis B virus
replication in vitro. Antimicrob Agents Chemother;40:1180-1185.
92. Lin E, Luscombe C, Wang Y, Shaw T and Locarnini S. 1996.
The guanine nucleoside analogue penciclovir is active against
chronic duck hepatitis B virus infection in vivo. Antimicrob Agents
Chemother;40:413-418.
93. Bowden DS, Moaven LD and Locarnini SA. 1996. New hepatitis
viruses: are there enough letters in the alphabet? Med J Aust;164:87-89.
94. Moaven LD, Bowden DS and Locarnini SA. 1995. Hepatitis G
virus and the hepatitis GB viruses. Todays Life Science;7:24-28.
95. Shaw T, Li J, Bowden DS, Cooksley G and Locarnini SA. 1995.
Serum guanase activity in hepatitis C virus infection. Purine
and Pyrimidine Metabolism in Man VIII:475-481.
96. Druce JD, Locarnini SA and Birch CJ. 1995. Infection control
practices. [Letter] Med J Aust;163:459-461.
97. Druce JD, Locarnini SA and Birch CJ. 1995. Syringe cleaning
techniques and transmission of HIV. AIDS;9:1105-1106.
98. Druce JD, Jardine D, Locarnini SA and Birch CJ. 1995. Susceptibility
of HIV to inactivation by disinfectants and ultraviolet light.
J Hosp Infect;30:167-180.
99. Anderson JS, Locarnini SA, Doherty RR, Breschkin AM, Dax
EM and Mijch AM. 1995. False-negative results for HIV-1. [Letter]
Med J Aust;162:220.
100. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S
and Locarnini S. 1995. The covalently closed duplex form of the
hepadnavirus genome exists in situ as a heterogeneous population
of viral minichromosomes. J Virol;69:3350-3357.
101. Druce J, Locarnini S and Birch C. 1995. Isolation of HIV-1
from experimentally contaminated multidose local anaesthetic vials.
Med J Aust;162:513-515.
102. Strasser S, Smith B, Watson K, Coghlan P, Locarnini S and
Desmond P. 1995. Evaluation of blood donors with equivocal hepatitis
C serological results. Med J Aust;162:459-461.
103. Heath T, Burrow J, Currie B, Bowden FJ, Fisher D, Demediuk
B, Locarnini S and Anderson D. 1995. Locally acquired hepatitis
E in the Northern Territory of Australia. Med J Aust;162:318-319.
104. McMillan J, Shaw T, Angus P and Locarnini S. 1995. Effect
of immunosuppressive and antiviral agents on hepatitis B virus
replication in vitro. Hepatology;22:36-43.
105. Crofts N, Stewart T, Hearne, P, Ping XY, Breschkin AM and
Locarnini SA. 1995. Spread of blood-borne viruses among Australian
prison entrants. Brit Med J;310:285-288.
106. Moaven L, Van Asten M, Crofts N and Locarnini S. 1995. Seroepidemiology
of hepatitis E in selected Australian populations. J Med Virol;45:326-330.
107. Mansell C and Locarnini S. 1995. Epidemiology of hepatitis
C in the East. Seminars in Liver Disease;15:15-32.
108. Wang Y, Luscombe C, Bowden S, Shaw T and Locarnini S. 1995.
Inhibition of duck hepatitis B virus DNA replication by antiviral
chemotherapy with ganciclovir - nalidixic acid. Antimicrob Agents
Chemother;39:556-558.
109. Angus PW, Locarnini S, McCaughan G, Jones RM, McMillan J,
Bowden S. 1995. Hepatitis B virus precore mutant infection is
associated with severe recurrent disease following liver transplantation.
Hepatology;21:14-18.
110. Shaw T and Locarnini S. 1995. Hepatic purine and pyrimidine
metabolism: Implications for the design of antiviral agents. Liver;15:169-184.
111. Dean J, Bowden S and Locarnini S. 1995. Reversion of duck
Hepatitis B Virus DNA replication in vivo following cessation
of treatment with the nucleoside analogue ganciclovir. Antiviral
Research;27:171-178.
112. Bowden FJ, Currie BJ, Miller NC, Locarnini SA and Krause
VL. 1994. Should aboriginals in the "top end" of the
Northern Territory be vaccinated against hepatitis A? Med J Aust;161:372-373.
113. Crofts N, Hopper JL, Milner RA, Breschkin AM, Bowden DS
and Locarnini SA. 1994. Blood-borne virus infections among Australian
injecting drug users: Implications for spread of HIV. Euro J Epidem;10:687-694.
114. Crofts N, Russell D, Dax E, Breschkin A, Milner R and Locarnini
S. 1994. Case report: HIV-2 infections in Victoria. Australian
HIV Surveillance Report;10:1-4.
115. Bartholomeusz A, Tomlinson E, Wright PJ, Birch C, Locarnini
S, Weigold H, Marcuccio S and Holan G. 1994. Use of a flavivirus
RNA dependent RNA polymerase assay to investigate the antiviral
activity of selected compounds. Antiviral Research;24:341-350.
116. Fan L, Hui Z, Sotirios K, Locarnini SA and Anderson DA.
1994. Persistent and transient responses to antibody to hepatitis
E virus detected by western immunoblot using open reading frame
2 and 3 and glutathione S-transferase fusion proteins. J Clin
Microbiol;32:2060-2066.
117. Shaw T, Amor P, Civitico G, Boyd M and Locarnini S. 1994.
In vitro antiviral activity of penciclovir, a novel purine nucleoside,
against duck hepatitis B virus. Antimicrob Agents Chemother;38:719-723.
118. Civitico G and Locarnini S. 1994. The half-life of duck
hepatitis B virus supercoiled DNA in congenitally infected primary
hepatocyte culture. Virology;203:81-89.
119. Luscombe C, Pedersen J, Bowden S and Locarnini S. 1994.
Alterations in intrahepatic expression of duck hepatitis B viral
markers with ganciclovir chemotherapy. Liver;14:182-192.
120. Breschkin A and Locarnini S. 1993. Comparison of three second
generation immunoassays for detection of hepatitis C virus antibody.
Australian Journal of Medical Science;14:17-21.
121. Jardine D, Tachedjian G, Locarnini S and Birch C. 1993.
Cellular topoisomerase I activity associated with HIV-1. AIDS
Research and Human Retroviruses;9:1245-1250.
122. Moaven LD, Fuller AJ, Doultree JC, Marshall JA, Bowden S,
Moeckli RA and Locarnini SA. 1993. A case of acute hepatitis E
in Victoria. Med J Aust;159:124-125.
123. Moaven, L. D., Crofts, N., Locarnini, S. A. 1993. Hepatitis
C virus infection in Victorian injecting drug users in 1971. Med
J Aust;158:574.
124. Crofts N, Hopper J, Bowden S, Moaven L, Breschkin A, Milner
R and Locarnini S. 1993. Hepatitis C virus infection among Victorian
injecting drug users. Med J Aust;159:237-241.
125. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones
B and Locarnini S. 1993. Combination antiviral therapy controls
severe post-liver transplant recurrence of hepatitis B virus infection.
J Gastro & Hepatol;8:353-357.
126. Niu J, Wang Y, Dixon R, Bowden S, Qiao M, Einck L and Locarnini
S. 1993. The use of ampligen alone and in combination with ganciclovir
and coumermycin A1 for the treatment of ducks congenitally infected
with duck hepatitis B virus. Antiviral Research;21:155-171.
127. Tachedjian G, Tyssen D, Jardine D, Locarnini S and Birch
C. 1991. Synergistic inhibition of human immunodeficiency virus
type 1 in vitro by alpha interferon and coumermycin A1. Antiviral
Chemistry and Chemotherapy;3:183-188.
128. Wang Y, Bowden D, Shaw T, Civitico G, Chan Y, Qiao M and
Locarnini S. 1991. Inhibition of duck hepatitis B virus replication
by ganciclovir. Antiviral Chemistry and Chemotherapy;2:107-114.
129. Locarnini S. 1991. Design of new antiviral agents for chronic
hepatitis B virus infection. J Gastro & Hepatol;6(Suppl. 1):18-22.
130. Niu J, Wang Y, Qiao M, Gowans E, Edwards P, Thyagarajan
SP, Gust I and Locarnini S. 1990. Effect of Phyllanthus amarus
on duck hepatitis B virus replication in vivo. JMed Virol;32:212-218.
131. Tachedjian G, Tyssen D, Locarnini S, Gust I and Birch C.
1990. Investigation of topoisomerase inhibitors for activity against
human immunodeficiency virus: inhibition by coumermycin A1. Antiviral
Chemistry and Chemotherapy;1:131-138.
132. Locarnini S, Civitico G, Wang Y, Tachedjian G and Gust I.
1990. Inhibition of duck hepatitis B viral supercoiled DNA by
topoisomerase and DNA gyrase inhibitors. Journal of Cellular Biochemistry.
Supplement;14D:62.
133. Bishop N, Civitico G, Wang Y, Luscombe C, Tachedjian G,
Gust I and Locarnini S. 1990. Antiviral strategies in chronic
hepatitis B infection: II. Inhibition of duck hepatitis B virus
in vitro using conventional antiviral agents and supercoiled-DNA
active compounds. J Med Virol;31:90-97.
134. Bishop N, Civitico G, Wang Y, Guo K, Birch C, Gust I and
Locarnini S. 1990. Antiviral strategies in chronic hepatitis B
infection: I: Establishment of an in vitro system using the duck
hepatitis B virus model. J Med Virol;31:82-89.
135. Locarnini SA, Guo K, Lucas R and Gust ID. 1989. Inhibition
of HBV DNA replication by ganciclovir in patients with AIDS. Lancet
ii:1225-1226.
136. Anderson DA, Ross BC and Locarnini SA. 1988. Restricted
replication of hepatitis A virus in cell culture: encapsidation
of viral RNA depletes the pool of RNA available for replication.
J Virol;62:4201-4206.
137. Anderson DA, Locarnini SA, Coulepis AG and Gust ID. 1985.
Restrictive events in the replication of hepatitis A virus in
vitro. Intervirology;24:26-32.
138. Gust ID, Lehmann NI, Crowe S, McCrorie M, Locarnini SA and
Lucas CR. 1985. The origin of the HM175 strain of hepatitis A
virus. J Infect Dis;151:365-366.
139. MacGregor A, Kornitschuk M, Hurrell JGR, Lehmann NI, Coulepis
AG, Locarnini SA and Gust ID. 1983. Monoclonal antibodies against
hepatitis A virus. J Clin Microbiol;18:1237-1243.
140. Zhuang Hui, Coulepis AG, Locarnini SA, Kaldor J, Marshall
JA and Gust ID. 1983. Characterization of a precipitating antigen
detected in the serum of patients with viral hepatitis. J Med
Virol;11:267-276.
141. Gust ID, Coulepis AG, Feinstone SM, Locarnini SA, Moritsugu
Y, Najera R and Siegl GG. 1983. Taxonomic classification of hepatitis
A virus. Intervirology;20:1-7.
142. Coulepis AG, Locarnini SA, Westaway EG, Tannock GA and Gust
ID. 1982. Biophysical and biochemical characterization of hepatitis
A virus. Intervirology;18:107-127.
143. Zhuang Hui, Kaldor J, Locarnini SA and Gust ID. 1982. Serum
immunoglobulin levels in acute A, B and non-A,non-B hepatitis.
Gastroenterology;82:549-553.
144. Zhuang Hui, Coulepis AG, Locarnini SA and Gust ID. 1982.
Detection of markers of hepatitis B infection in serum dried onto
filter paper: an application to field studies. Bull. WHO;60:783-787.
145. Locarnini SA, Coulepis AG, Westaway EG and Gust ID. 1981.
Restricted replication of human hepatitis A virus in cell culture:
An intracellular biochemical study. J Virol;37:216-225.
146. Pedersen JS, Toh BH, Locarnini SA, Gust ID and Shyamala
GNS. 1981. Autoantibody to intermediate filaments in viral hepatitis.
Clin Immunol Immunopathol;21:154-161.
147. Coulepis AG, Tannock GA, Locarnini SA and Gust ID. 1981.
Evidence that the genome of hepatitis A virus consists of single-stranded
RNA. J Virol;37:473-477.
148. Adler B, Murphy AM, Locarnini SA and Faine S. 1980. Detection
of specific anti-leptospiral Immunoglobulins M & G in human
serum by solid-phase enzyme-linked immunosorbent assay. J Clin
Microbiol;11:452-457.
149. Coulepis AG, Locarnini SA and Gust ID. 1980. Iodination
of hepatitis A virus reveals a fourth structural polypeptide.
J Virol;35:572-574.
150. Locarnini SA, Coulepis AG, Kaldor J and Gust ID. 1980. Coproantibodies
in hepatitis A: Detection by enzyme-linked immunosorbent assay
and immune electron microscopy. J Clin Microbiol;11:710-716.
151. Coulepis AG, Locarnini SA, Lehmann NI and Gust ID. 1980.
Detection of hepatitis A virus in the feces of patients with naturally-acquired
infection. J Infect Dis;141:151-156.
152. Garland SM, Locarnini SA and Gust ID. 1979. A solid-phase
enzyme-linked immunosorbent assay (ELISA) for detection of antibody
to rubella virus. Pathology;11:393-399.
153. Locarnini SA, Coulepis AG, Stratton AM, Kaldor J and Gust
ID. 1979. Solid-phase enzyme-linked immunosorbent assay for detection
of hepatitis A specific immunoglobulin. J Clin Microbiol;9:459-465.
154. Locarnini SA, Garland SM, Lehmann NI, Pringle RC and Gust
ID. 1978. Solid phase enzyme linked immunosorbent assay for detection
of hepatitis A virus. J Clin Microbiol;8:277-282.
155. Locarnini SA, Coulepis AG, Ferris AA, Lehmann NI and Gust
ID. 1978. Purification of hepatitis A virus from human faeces.
Intervirology;10:300-308.
156. Coulepis AG, Locarnini SA, Ferris AA, Lehmann NI and Gust
ID. 1978. The polypeptides of hepatitis A virus. Intervirology;10:24-31.
157. Wosu LO, Locarnini SA and Johnson RH. 1978. Attempts to
isolate a parvovirus from faecal specimens of patients with hepatitis
A. Aust J Exp Biol Med Sci;56:123-126.
158. Locarnini SA and Gust ID. 1978. Food and hepatitis A. Food
Technol Aust.;30:295-298.
159. Locarnini SA, Ferris AA, Lehmann NI and Gust ID. 1977. The
antibody response following hepatitis A infection. Intervirology;8:309-318.
160. Locarnini SA, Gust ID, Ferris AA, Stott AC and Wong ML.
1976. A prospective study of acute viral hepatitis with particular
reference to hepatitis A. Bull Wld Hlth Org.;54:199-206.
161. Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA and
Gust ID. 1974. Enterovirus type 71 infection in Melbourne. Bull
Wld Hlth Org;51:609-615.
162. Locarnini SA, Ferris AA, Stott AC and Gust ID. 1974. The
relationship between a 27 nm virus-like particle and hepatitis
A as demonstrated by immune electron microscopy. Intervirology;4:110-118.
163. Locarnini SA, Ferris AA, Stott AC and Gust ID. 1974. Pitfalls
in hepatitis A? Lancet ii: 1007.
Invited Editorials
1. Thompson, A., Locarnini, S., Visvanathan, K. 2007. The natural
history and the staging of chronic hepatitis B: time for re-evaluation
of the virus-host relationship based on molecular virology and
immunopathogenesis considerations? Gastroenterology;113:1031-1035.
2. Locarnini S. 2005. Therapies for HBV: Where to from here?
Gastroenterology;128:789-792.
3. Shaw T, Bowden S, Locarnini S, 2004. Rescue therapy for drug
resistant hepatitis B: another argument for chemotherapy? Gastroenterology;126:343-347.
4. Angus P and Locarnini S. 2004. Lamivudine-resistant hepatitis
B virus and ongoing lamivudine therapy: stop the merry-go-round,
it’s time to get off! Antiviral Therapy;9:145-148.
5. Bowden S, Bartholomeusz A, Locarnini, S. 2003. Lamivudine
resistant occult HBV implications for Public Health. J Hepatol;38:526-528.
6. Shaw T, Bowden S, Locarnini S. 2002. Chemotherapy for hepatitis
B: new treatment options necessitate reappraisal of traditional
endpoints. Gastroenterology;123:2135-2140.
7. Bartholomeusz, A, Locarnini S. 2001. Hepatitis B virus mutants
and fulminant hepatitis B: Fitness plus phenotype. Hepatology;34:432-435.
8. Shaw T and Locarnini, S. 2000. Combination chemotherapy for
hepatitis B virus: The final solution? Hepatology;32:430-432
9. Bowden S and Locarnini S. 1999. TT virus: An agent of transfusion-associated
hepatitis or yellow herring? J Gastro Hepatol;14:299-300.
10. Locarnini S, 1998. Hepatitis B virus surface and polymerase
gene variants: potential virological and clinical significance.
Hepatology;27:294-297.
11. Locarnini S. 1997. The attachment receptor for hepatitis
A. Trends in Microbiology;5:47-48 (discussion).
12. Catton M and Locarnini SA. 1994. Influenza Vaccination: Exploding
the myths. Aus Fam Phys;23:289-291.
13. Locarnini, S., MacIntyre, R. 1993. Influenza--the need for
vaccination. Aus Fam Phys;22:85.
Book Chapters/Reviews
1. Gish, R., Locarnini, S. 2007. Genotyping and Genomic Sequencing
in Clinical Practice. Clin Liver Dis;11:761-795
2. Thompson, A., Locarnini, S. 2007. Toll-like receptors, RIG-I-like
RNA helicases and the antiviral innate immune response. Immunol
Cell Biol;85:435-445
3. Thio, C. L, Locarnini, S. 2007. Treatment of HIV/HBV coinfection:
clinical and virologic issues. AIDS Rev;9:40-53
4. Sasadeusz, J. J., Locarnini, S., Macdonald, G. 2007. Why do
we not yet have combination chemotherapy for chronic hepatitis
B?. Med J Aust;186:204-206
5. Locarnini, S and Omata, M. 2006. Molecular virology of hepatitis
B virus and the development of antiviral drug resistance. Liver
Int;26(Suppl.2):11-22
6. Bartholomeusz, A. and S. Locarnini. 2006. Hepatitis B virus
mutations associated with antiviral therapy. J Med Virol;78(Suppl
1):S52-5
7. Bartholomeusz, A. and S.A. Locarnini. 2006. Antiviral drug
resistance: clinical consequences and molecular aspects. Semin
Liver Dis;26:162-70
8. Gish, R.G. and S.A. Locarnini. 2006. Chronic hepatitis B:
current testing strategies. Clin Gastroenterol Hepatol;4:666-76
9. Shaw T., Bartholomeusz, A., Locarnini, S. 2006. HBV drug resistance:
mechanisms, detection and interpretation. J Hepatol;44:593-606
10. Locarnini. S. and Mason. W. S. 2006. Cellular and virological
mechanisms of HBV drug resistance. J Hepatol;44:422-431
11. Shaw T, Locarnini S. 2004. Entecavir for the treatment of
chronic hepatitis B. Expert Rev Anti Infect Ther;2:853-871.
12. Shaw T, Locarnini S. 2004. Problems inherent to antiviral
therapy. In: Milestones in Drug Therapy. Eds. Colacino JM, Heinz
BA. Birkhauser, Basel, Switzerland.
13. Beard MR, Locarnini S. 2004. Monitoring gene expression using
DNA microarrays during hepatitis infection. Methods Mol Med;96:55-64.
14. Shaw T, Locarnini S. 2004. A parsimonious method for screening
drug combinations for antihepadnaviral activity using a parametric
dose-response surface approach. Methods Mol Med;96:387-413.
15. Gish R, Locarnini S. 2004. Studying the treatment of chronic
hepatitis B viral infection in special populations. Methods Mol
Med;96:465-498.
16. Bowden S, Jackson K, Littlejohn M, Locarnini S. 2004. Quantification
of HBV covalently closed circular DNA from liver tissue by real-time
PCR. Methods Mol Med;95:41-50.
17. Ayres A, Locarnini S, Bartholomeusz A. 2004. HBV genotyping
and analysis for unique mutations. Methods Mol Med;95:125-49.
18. Shaw T and Locarnini S. 2004. Hepatitis B. Encyclopedia of
Gastroenterology p315-322. Leonard R. Johnson (Editor). Publisher:
Academic Press (November, 2003)
19. Lee JY, Locarnini S. 2004. Hepatitis B virus: pathogenesis,
viral intermediates and viral replication. Clin Liver Dis;8:301-320.
20. Locarnini S. 2004. Molecular virology of hepatitis B virus.
Semin Liver Dis;24(Suppl 1):3-10.
21. Feld, J, Lee, J-Y, Locarnini S. 2003. New targets and possible
new therapeutic approaches in the chemotherapy of chronic hepatitis
B. Hepatology;38:545-553.
22. Chin R and Locarnini S. 2003. Treatment of chronic hepatitis
B: Current challenges and future directions. Rev Med Virol;13:255-272.
23. Bartholomeusz, A, Furman, P, Locarnini, S. 2003. Novel approaches
in the management of chronic HBV infection. In: Frontiers in Viral
Hepatitis. Eds. RF Schinazi, JP Sommadossi, CM Wright. p.225-243.i
24. Locarnini S, McMillan J and Bartholomeusz A. 2003. The hepatitis
B virus and common mutants. Seminars in Liver Disease;23:5-20.
25. Locarnini S. 2003. Hepatitis B viral resistance: mechanisms
and diagnosis. J Hepatol;39(Suppl 1):S124-132.
26. Chen, RY, Desmond, PV, Locarnini SA. 2002. Emerging therapies
of hepatitis B and C. J Gastroenterol Hepatol;17:S471-481.
27. Lewin S, Walters T, Locarnini S. 2002. Hepatitis B treatment:
rational combination chemotherapy based on viral kinetic and animal
model studies. Antiviral Res;55:381-396.
28. Feld J and Locarnini S. 2002. Antiviral therapy for hepatitis
B virus infections: New targets and technical challenges. J Clinical
Virol;25:267-83.
29. Locarnini S. 2002. Mechanisms of drug-resistance and novel
approaches to therapy for chronic hepatitis C. J Gastro &
Hepatol;17(Suppl 3):S351-359.
30. Locarnini S. 2002. Clinical relevance of viral dynamics and
genotypes in HBV. 2002. J Gastro & Hepatol;17(Suppl 3):S322-328.
31. Delaney WE IV, Locarnini SA, Bartholomeusz A. 2002. Evolving
therapies for the treatment of chronic hepatitis B virus infection.
Expert Opinion on Investigational Drugs;11:169-187.
32. Locarnini, SA, Bartholomeusz A. 2002. Advances in Hepatitis
C: What is coming in the next five years. J of Gastro & Hepatol;17:442-447.
33. Lai CL, Yuen MF, Locarnini SA. Treatment of chronic hepatitis
B. In: HBV Guide. 2002. Eds. Lai CL and Locarnini SA. International
Medical Press, London, UK;14:193-218.
34. Delaney, WE, Shaw, T, Locarnini, S. 2001. Resistance of hepatitis
B virus to antiviral Drugs: Current aspects and directions for
future investigation. Antiviral Chemistry & Chemother;12:1-35.
35. Batey R, Chen R, Lee J-Y, Locarnini S, McCoy R, Richmond
J, Sievert W and Sasadeusz J. 2001. Treatments for hepatitis C.
In: National Hepatitis C Resource Manual, p 117-138. Commonwealth
Department of Health and Aged Care, Canberra.
36. Aitken C, Australian Hepatitis Council, Australian Intravenous
League, Boyce N, Carruthers S, Chen R, Crofts N, Locarnini S,
MacKintosh A, McDonald M, Ridge A, Sansom D, Speed T, Woodruff
J. 2001. Reducing hepatitis C transmission in the community. In:
“National Hepatitis C Resource Manual”, pp 47-74.
Commonwealth Department of Health and Aged Care, Canberra.
37. Locarnini, S. 2000. Molecular pathogenesis of viral hepatitis.
J Gastro Hepatol;15:G46-8.
38. Shaw T and Locarnini, S. 2000. Combination chemotherapy for
the treatment of chronic hepatitis B virus the path forward? Drugs;60:517-531.
39. Locarnini, S. 2000. A virological perspective on the need
for vaccination. J Viral Hepatitis;7(Suppl.1):5-6.
40. Torresi, J, Locarnini, S. 2000. Antiviral chemotherapy for
the treatment of hepatitis B virus infections. Gastroenterology;118:(Suppl
2):S83-103.
41. WHO Technical Advisory Group on Hepatitis C. 1999. Global
Surveillance and Control of Hepatitis C. J Viral Hepatitis;6:35-47.
42. Marinos G, Pirola R, Locarnini S. 1999. Acute Hepatitis C.
Aust Family Phys;28:S124-S126.
43. Shaw T and Locarnini SA. 1999. Preclinical Aspects of Lamivudine
and Famciclovir against Hepatitis B Virus. J Viral Hepatitis;6:89-106.
44. Locarnini S and Birch C. 1999. Antiviral Chemotherapy for
Chronic Hepatitis B Infection: Lessons Learned from Treating HIV
Infected Patients. J.Hepatol;30:536-550.
45. Torresi J and Locarnini SA. 1999. New therapeutic strategies
in the treatment of hepatitis B virus infection. Exp Opin Invest
Drugs;8:289-288.
46. Siebert D, Locarnini S and Cunningham A. 1998. Viral Hepatitis
and Pregnancy. Viral Infections in Obstetrics and Gynaecology;10:165-217.
47. Chin R and Locarnini S. 1998. New therapies for the treatment
of chronic hepatitis B infection. Curr Opin Infect Dis;11:719-726.
48. Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi F
and Locarnini S. 1998. Mutations in the hepatitis B virus DNA
polymerase associated with antiviral resistance. Int Antiviral
News;6:167-169.
49. Bartholomeusz A, Schinazi R and Locarnini S. 1998. Significance
of mutations in the hepatitis B virus polymerase selected by nucleoside
analogues and implications for controlling chronic disease. Viral
Hepatitis Reviews;4:167-187
50. Torresi J and Locarnini SA. 1997. The epidemiology, natural
history and virology of hepatitis E virus. Aust Chinese Med Assoc;2:6.1-6.4
51. Nicoll A and Locarnini S. 1997. Present and future directions
in the treatment of chronic hepatitis B infection. J Gastro Hepatol;12:843-854.
52. Bartholomeusz A and Locarnini S. 1997. Mutations in the hepatitis
B virus polymerase gene that are associated with resistance to
famciclovir and lamivudine. Int. Antiviral News;5:123-124.
53. Locarnini SA and Newbold JE. 1997. Chronic hepatitis B: The
therapeutic challenge. Editorial, The Journal of Antimicrobial
Chemotherapy;39:559-562.
54. Luscombe C and Locarnini SA. 1996. The mechanism of action
of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews;2:1-35.
55. Locarnini S and McAnulty J. 1996. Surveillance for Hepatitis
C. Editorial: Communicable Diseases Intelligence;20:32-33.
56. Locarnini SA, Civitico G and Newbold J. 1996. Hepatitis B:
New approaches for antiviral chemotherapy. Antiviral Chem &
Chemother;7:53-64.
57. Locarnini S and Civitico G. 1993. Hepatitis B virus supercoiled
DNA: inhibition by nalidixic acid-ganciclovir combination antiviral
chemotherapy. Int Antiviral News;1:117-118.
58. Breschkin AM, Bowden DS and Locarnini SA. 1993. Testing issues
in hepatitis C diagnostics. Today's Life Science;5:26-33.
59. Locarnini S. 1993. Antiviral Drugs: Mechanisms of Action.
Australian Prescriber;16:78-81.
60. Locarnini S, Civitico G, Wang Y, Tachedjian G and Gust I.
1991. Mechanism of action of antiviral agents targeted against
duck hepatitis B virus supercoiled DNA. In: The 1990 International
Symposium on Viral Hepatitis and Liver Disease. Ed. FB Hollinger,
SM Lemon and H Margolis. Williams and Wilkins, Maryland, p669-671.
61. Locarnini S. 1990. Antiviral chemotherapy in hepatitis B
virus infections. Todays Life Science;2:32-39.
62. Anderson DA, Locarnini SA and Gust ID. 1988. Replication
of hepatitis A virus. In Viral Hepatitis and Liver Disease. Ed.
Zuckerman AJ, p8-11, Alan R Liss,New York.
63. Anderson DA, Locarnini SA, Ross BC, Coulepis AG, Anderson
BN and Gust ID. 1987. Single cycle growth kinetics of hepatitis
A virus in BSC-1 cells. In, Positive Strand RNA Viruses, UCLA
Symposia on Molecular and Cellular Biology, Volume 54. Editors,
MA Brinton and RR Rueckert, p497-507. Alan R Liss, New York.
64. Gust ID, Lehmann NI, Coulepis AG and Locarnini SA. 1982.
Epidemiological studies on hepatitis A in Melbourne. Ibid, p734.
65. Locarnini SA, Coulepis AG, Zhuang Hui, Westaway EG and Gust
ID. 1982. Characterization of the replication cycle of hepatitis
virus in vitro. In, Viral Hepatitis, 1981 International Symposium.
Eds. Szmuness W, Alter HJ and Maynard JE. p31-47, Franklin Institute
Press, Philadelphia.
66. Lucas CR, Gust ID, McCrorie M, Lehmann NI, Dimitrakakis M
and Locarnini SA. 1980. Non-A, non-B hepatitis, epidemiological
and clinical features. In: Proceedings First International Symposium
on non-A, non-B hepatitis, Vienna.
67. Gust ID, Lehmann NI, Lucas CR, Ferris AA & Locarnini
SA. 1978. Studies on the epidemiology of hepatitis A in Melbourne.
In Viral Hepatitis, eds. Vyas GN, Cohen SA and Schmid R. p105-112,
the Franklin Institute Press, Pennsylvania.
68. Gust ID, Lehmann NI, Ferris AA and Locarnini SA. 1978. Epidemiology
of hepatitis type A. In Hepatitis Viruses, ed. Oda T, p13-27,
University of Tokyo Press, Tokyo.
69. Ferris AA, Stott AC and Locarnini SA. 1974. Studies of "faecal
antigen" in viral hepatitis type A. In Hepatitis B, ed. Logan
GE. p277-285,Abbott Laboratories, Sydney.
